慢性淋巴细胞白血病(CLL)是西方国家最常见的白血病类型,占65岁以上白血病患者的40%。在WHO分类中,CLL特指B细胞恶性疾病,而以前的T-CLL被命名为T细胞幼淋白血病[1]。CLL患者是一个异质性群体,在发病形式、疾病进展、治疗反应和生存期方面具有明显的个体差异。传统的临床分期并 Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries, accounting for 40% of patients over the age of 65 with leukemia. In the WHO classification, CLL refers specifically to B-cell malignancies, whereas previous T-CLL was named as T-cell leukemia [1]. CLL patients are a heterogeneous population with significant individual differences in the form of disease, disease progression, treatment response, and survival. Traditional clinical staging and